MedPage Today -- Using vascular endothelial growth factor (VEGF) blockers to treat neovascular age-related macular degeneration does not appear to increase the risk of serious cardiovascular events, a retrospective study showed.
MedPage Today -- Using vascular endothelial growth factor (VEGF) blockers to treat neovascular age-related macular degeneration does not appear to increase the risk of serious cardiovascular events, a retrospective study showed.